{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:28:12Z","timestamp":1790022492068,"version":"4.0.1"},"reference-count":193,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T00:00:00Z","timestamp":1609718400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T00:00:00Z","timestamp":1609718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"General Research Fund","award":["17123718"],"award-info":[{"award-number":["17123718"]}]},{"name":"General Research Fund","award":["17118619"],"award-info":[{"award-number":["17118619"]}]},{"DOI":"10.13039\/501100005847","name":"Health and Medical Research Fund","doi-asserted-by":"crossref","award":["05161826"],"award-info":[{"award-number":["05161826"]}],"id":[{"id":"10.13039\/501100005847","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81870247"],"award-info":[{"award-number":["81870247"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81800245"],"award-info":[{"award-number":["81800245"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The prevalence of cardiomyopathy is higher in diabetic patients than those without diabetes. Diabetic cardiomyopathy (DCM) is defined as a clinical condition of abnormal myocardial structure and performance in diabetic patients without other cardiac risk factors, such as coronary artery disease, hypertension, and significant valvular disease. Multiple molecular events contribute to the development of DCM, which include the alterations in energy metabolism (fatty acid, glucose, ketone and branched chain amino acids) and the abnormalities of subcellular components in the heart, such as impaired insulin signaling, increased oxidative stress, calcium mishandling and inflammation. There are no specific drugs in treating DCM despite of decades of basic and clinical investigations. This is, in part, due to the lack of our understanding as to how heart failure initiates and develops, especially in diabetic patients without an underlying ischemic cause. Some of the traditional anti-diabetic or lipid-lowering agents aimed at shifting the balance of cardiac metabolism from utilizing fat to glucose have been shown inadequately targeting multiple aspects of the conditions. Peroxisome proliferator-activated receptor \u03b1 (PPAR\u03b1), a transcription factor, plays an important role in mediating DCM-related molecular events. Pharmacological targeting of PPAR\u03b1 activation has been demonstrated to be one of the important strategies for patients with diabetes, metabolic syndrome, and atherosclerotic cardiovascular diseases. The aim of this review is to provide a contemporary view of PPAR\u03b1 in association with the underlying pathophysiological changes in DCM. We discuss the PPAR\u03b1-related drugs in clinical applications and facts related to the drugs that may be considered as risky (such as fenofibrate, bezafibrate, clofibrate) or safe (pemafibrate, metformin and glucagon-like peptide 1-receptor agonists) or having the potential (sodium\u2013glucose co-transporter 2 inhibitor) in treating DCM.<\/jats:p>","DOI":"10.1186\/s12933-020-01188-0","type":"journal-article","created":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T21:03:44Z","timestamp":1609794224000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":110,"title":["Impact of peroxisome proliferator-activated receptor-\u03b1 on diabetic cardiomyopathy"],"prefix":"10.1186","volume":"20","author":[{"given":"Lin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liguo","family":"Jian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Wai","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7002-5524","authenticated-orcid":false,"given":"Zhengyuan","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,4]]},"reference":[{"issue":"4","key":"1188_CR1","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","volume":"122","author":"G Jia","year":"2018","unstructured":"Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res. 2018;122(4):624\u201338.","journal-title":"Circ Res"},{"issue":"14","key":"1188_CR2","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1113\/JP276747","volume":"598","author":"M Nakamura","year":"2020","unstructured":"Nakamura M, Sadoshima J. Cardiomyopathy in obesity, insulin resistance and diabetes. J Physiol. 2020;598(14):2977\u201393.","journal-title":"J Physiol"},{"issue":"3","key":"1188_CR3","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/nrendo.2015.216","volume":"12","author":"G Jia","year":"2016","unstructured":"Jia G, DeMarco VG, Sowers JR. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nat Rev Endocrinol. 2016;12(3):144\u201353.","journal-title":"Nat Rev Endocrinol"},{"issue":"19","key":"1188_CR4","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1080\/15384101.2017.1371886","volume":"16","author":"Y Cai","year":"2017","unstructured":"Cai Y, Kandula V, Kosuru R, Ye X, Irwin MG, Xia Z. Decoding telomere protein Rap1: Its telomeric and nontelomeric functions and potential implications in diabetic cardiomyopathy. Cell Cycle. 2017;16(19):1765\u201373.","journal-title":"Cell Cycle"},{"issue":"4","key":"1188_CR5","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1093\/cvr\/cvx018","volume":"113","author":"CR Chong","year":"2017","unstructured":"Chong CR, Clarke K, Levelt E. Metabolic remodeling in diabetic cardiomyopathy. Cardiovasc Res. 2017;113(4):422\u201330.","journal-title":"Cardiovasc Res"},{"issue":"25","key":"1188_CR6","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1161\/CIRCULATIONAHA.106.679597","volume":"115","author":"S Boudina","year":"2007","unstructured":"Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation. 2007;115(25):3213\u201323.","journal-title":"Circulation"},{"issue":"17","key":"1188_CR7","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1089\/ars.2015.6305","volume":"22","author":"MM Sung","year":"2015","unstructured":"Sung MM, Hamza SM, Dyck JR. Myocardial metabolism in diabetic cardiomyopathy: potential therapeutic targets. Antioxid Redox Signal. 2015;22(17):1606\u201330.","journal-title":"Antioxid Redox Signal"},{"issue":"6","key":"1188_CR8","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.2337\/dc06-2429","volume":"30","author":"G Perseghin","year":"2007","unstructured":"Perseghin G, Ntali G, De Cobelli F, Lattuada G, Esposito A, Belloni E, Canu T, Costantino F, Ragogna F, Scifo P, et al. Abnormal left ventricular energy metabolism in obese men with preserved systolic and diastolic functions is associated with insulin resistance. Diabetes Care. 2007;30(6):1520\u20136.","journal-title":"Diabetes Care"},{"issue":"2","key":"1188_CR9","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/S0735-1097(03)00625-9","volume":"42","author":"M Diamant","year":"2003","unstructured":"Diamant M, Lamb HJ, Groeneveld Y, Endert EL, Smit JW, Bax JJ, Romijn JA, de Roos A, Radder JK. Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol. 2003;42(2):328\u201335.","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"1188_CR10","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1161\/01.CIR.0000072789.89096.10","volume":"107","author":"M Scheuermann-Freestone","year":"2003","unstructured":"Scheuermann-Freestone M, Madsen PL, Manners D, Blamire AM, Buckingham RE, Styles P, Radda GK, Neubauer S, Clarke K. Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation. 2003;107(24):3040\u20136.","journal-title":"Circulation"},{"issue":"5","key":"1188_CR11","doi-asserted-by":"publisher","first-page":"E1104-13","DOI":"10.1152\/ajpendo.2000.279.5.E1104","volume":"279","author":"DD Belke","year":"2000","unstructured":"Belke DD, Larsen TS, Gibbs EM, Severson DL. Altered metabolism causes cardiac dysfunction in perfused hearts from diabetic (db\/db) mice. Am J Physiol Endocrinol Metab. 2000;279(5):E1104-13.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"1","key":"1188_CR12","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12933-019-0892-3","volume":"18","author":"GM Uddin","year":"2019","unstructured":"Uddin GM, Zhang L, Shah S, Fukushima A, Wagg CS, Gopal K, Al Batran R, Pherwani S, Ho KL, Boisvenue J, et al. Impaired branched chain amino acid oxidation contributes to cardiac insulin resistance in heart failure. Cardiovasc Diabetol. 2019;18(1):86.","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"1188_CR13","doi-asserted-by":"publisher","first-page":"E1046-e52","DOI":"10.1152\/ajpendo.00097.2018","volume":"315","author":"N Fillmore","year":"2018","unstructured":"Fillmore N, Wagg CS, Zhang L, Fukushima A, Lopaschuk GD. Cardiac branched-chain amino acid oxidation is reduced during insulin resistance in the heart. Am J Physiol Endocrinol Metab. 2018;315(5):E1046-e52.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"4","key":"1188_CR14","doi-asserted-by":"publisher","first-page":"C1370-8","DOI":"10.1152\/ajpcell.00422.2006","volume":"292","author":"N F\u00fcl\u00f6p","year":"2007","unstructured":"F\u00fcl\u00f6p N, Mason MM, Dutta K, Wang P, Davidoff AJ, Marchase RB, Chatham JC. Impact of Type 2 diabetes and aging on cardiomyocyte function and O-linked N-acetylglucosamine levels in the heart. Am J Physiol Cell Physiol. 2007;292(4):C1370-8.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"4","key":"1188_CR15","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.cardiores.2006.11.033","volume":"73","author":"Z Xia","year":"2007","unstructured":"Xia Z, Kuo KH, Nagareddy PR, Wang F, Guo Z, Guo T, Jiang J, McNeill JH. N-acetylcysteine attenuates PKCbeta2 overexpression and myocardial hypertrophy in streptozotocin-induced diabetic rats. Cardiovasc Res. 2007;73(4):770\u201382.","journal-title":"Cardiovasc Res"},{"issue":"5","key":"1188_CR16","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1007\/s00125-012-2495-3","volume":"55","author":"K Huynh","year":"2012","unstructured":"Huynh K, Kiriazis H, Du XJ, Love JE, Jandeleit-Dahm KA, Forbes JM, McMullen JR, Ritchie RH. Coenzyme Q10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db\/db mouse model of type 2 diabetes. Diabetologia. 2012;55(5):1544\u201353.","journal-title":"Diabetologia"},{"key":"1188_CR17","first-page":"9257291","volume":"2017","author":"S Wang","year":"2017","unstructured":"Wang S, Wang C, Yan F, Wang T, He Y, Li H, Xia Z, Zhang Z. N-Acetylcysteine attenuates diabetic myocardial ischemia reperfusion injury through inhibiting excessive autophagy. Mediators Inflamm. 2017;2017:9257291.","journal-title":"Mediators Inflamm"},{"issue":"8","key":"1188_CR18","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1161\/01.CIR.101.8.899","volume":"101","author":"K Mizushige","year":"2000","unstructured":"Mizushige K, Yao L, Noma T, Kiyomoto H, Yu Y, Hosomi N, Ohmori K, Matsuo H. Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation. 2000;101(8):899\u2013907.","journal-title":"Circulation"},{"issue":"16","key":"1188_CR19","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/j.jacc.2009.04.074","volume":"54","author":"LJ Rijzewijk","year":"2009","unstructured":"Rijzewijk LJ, van der Meer RW, Lamb HJ, de Jong HW, Lubberink M, Romijn JA, Bax JJ, de Roos A, Twisk JW, Heine RJ, et al. Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J Am Coll Cardiol. 2009;54(16):1524\u201332.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"1188_CR20","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1056\/NEJMoa031314","volume":"350","author":"KF Petersen","year":"2004","unstructured":"Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med. 2004;350(7):664\u201371.","journal-title":"N Engl J Med"},{"key":"1188_CR21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.metabol.2017.08.005","volume":"77","author":"Y Mizuno","year":"2017","unstructured":"Mizuno Y, Harada E, Nakagawa H, Morikawa Y, Shono M, Kugimiya F, Yoshimura M, Yasue H. The diabetic heart utilizes ketone bodies as an energy source. Metabolism. 2017;77:65\u201372.","journal-title":"Metabolism"},{"issue":"7","key":"1188_CR22","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1161\/CIRCULATIONAHA.113.008476","volume":"130","author":"D Montaigne","year":"2014","unstructured":"Montaigne D, Marechal X, Coisne A, Debry N, Modine T, Fayad G, Potelle C, El Arid JM, Mouton S, Sebti Y, et al. Myocardial contractile dysfunction is associated with impaired mitochondrial function and dynamics in type 2 diabetic but not in obese patients. Circulation. 2014;130(7):554\u201364.","journal-title":"Circulation"},{"issue":"3","key":"1188_CR23","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1378\/chest.115.3.867","volume":"115","author":"WS Aronow","year":"1999","unstructured":"Aronow WS, Ahn C. Incidence of heart failure in 2,737 older persons with and without diabetes mellitus. Chest. 1999;115(3):867\u20138.","journal-title":"Chest"},{"issue":"1","key":"1188_CR24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0002-9149(74)90089-7","volume":"34","author":"WB Kannel","year":"1974","unstructured":"Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34(1):29\u201334.","journal-title":"Am J Cardiol"},{"issue":"11","key":"1188_CR25","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/S0002-9149(97)89163-1","volume":"77","author":"DM Shindler","year":"1996","unstructured":"Shindler DM, Kostis JB, Yusuf S, Quinones MA, Pitt B, Stewart D, Pinkett T, Ghali JK, Wilson AC. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol. 1996;77(11):1017\u201320.","journal-title":"Am J Cardiol"},{"issue":"23","key":"1188_CR26","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1053\/euhj.2000.2311","volume":"21","author":"L Ryd\u00e9n","year":"2000","unstructured":"Ryd\u00e9n L, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Packer M, Poole-Wilson PA. Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Eur Heart J. 2000;21(23):1967\u201378.","journal-title":"Eur Heart J"},{"issue":"3","key":"1188_CR27","doi-asserted-by":"publisher","first-page":"612","DOI":"10.2337\/diacare.28.3.612","volume":"28","author":"IS Thrainsdottir","year":"2005","unstructured":"Thrainsdottir IS, Aspelund T, Thorgeirsson G, Gudnason V, Hardarson T, Malmberg K, Sigurdsson G, Ryd\u00e9n L. The association between glucose abnormalities and heart failure in the population-based Reykjavik study. Diabetes Care. 2005;28(3):612\u20136.","journal-title":"Diabetes Care"},{"issue":"6785","key":"1188_CR28","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/35013000","volume":"405","author":"S Kersten","year":"2000","unstructured":"Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature. 2000;405(6785):421\u20134.","journal-title":"Nature"},{"issue":"5","key":"1188_CR29","doi-asserted-by":"publisher","first-page":"177","DOI":"10.4239\/wjd.v4.i5.177","volume":"4","author":"JM Pappachan","year":"2013","unstructured":"Pappachan JM, Varughese GI, Sriraman R, Arunagirinathan G. Diabetic cardiomyopathy: pathophysiology, diagnostic evaluation and management. World J Diabetes. 2013;4(5):177\u201389.","journal-title":"World J Diabetes"},{"issue":"11","key":"1188_CR30","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1161\/01.CIR.94.11.2837","volume":"94","author":"MN Sack","year":"1996","unstructured":"Sack MN, Rader TA, Park S, Bastin J, McCune SA, Kelly DP. Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation. 1996;94(11):2837\u201342.","journal-title":"Circulation"},{"issue":"6","key":"1188_CR31","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1074\/jbc.M106054200","volume":"277","author":"FM Campbell","year":"2002","unstructured":"Campbell FM, Kozak R, Wagner A, Altarejos JY, Dyck JR, Belke DD, Severson DL, Kelly DP, Lopaschuk GD. A role for peroxisome proliferator-activated receptor alpha (PPARalpha) in the control of cardiac malonyl-CoA levels: reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPARalpha are associated with higher concentrations of malonyl-CoA and reduced expression of malonyl-CoA decarboxylase. J Biol Chem. 2002;277(6):4098\u2013103.","journal-title":"J Biol Chem"},{"issue":"3","key":"1188_CR32","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.diabres.2013.01.008","volume":"100","author":"TI Lee","year":"2013","unstructured":"Lee TI, Kao YH, Chen YC, Huang JH, Hsiao FC, Chen YJ. Peroxisome proliferator-activated receptors modulate cardiac dysfunction in diabetic cardiomyopathy. Diabetes Res Clin Pract. 2013;100(3):330\u20139.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"1188_CR33","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1172\/JCI0214080","volume":"109","author":"BN Finck","year":"2002","unstructured":"Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, Han X, Gross RW, Kozak R, Lopaschuk GD, et al. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest. 2002;109(1):121\u201330.","journal-title":"J Clin Invest"},{"issue":"13","key":"1188_CR34","doi-asserted-by":"publisher","first-page":"7473","DOI":"10.1073\/pnas.96.13.7473","volume":"96","author":"TC Leone","year":"1999","unstructured":"Leone TC, Weinheimer CJ, Kelly DP. A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci U S A. 1999;96(13):7473\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"1188_CR35","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.amjcard.2003.12.026","volume":"93","author":"JK Boyer","year":"2004","unstructured":"Boyer JK, Thanigaraj S, Schechtman KB, P\u00e9rez JE. Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am J Cardiol. 2004;93(7):870\u20135.","journal-title":"Am J Cardiol"},{"issue":"1","key":"1188_CR36","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.amjcard.2005.07.111","volume":"97","author":"B Shivalkar","year":"2006","unstructured":"Shivalkar B, Dhondt D, Goovaerts I, Van Gaal L, Bartunek J, Van Crombrugge P, Vrints C. Flow mediated dilatation and cardiac function in type 1 diabetes mellitus. Am J Cardiol. 2006;97(1):77\u201382.","journal-title":"Am J Cardiol"},{"issue":"10","key":"1188_CR37","doi-asserted-by":"publisher","first-page":"490","DOI":"10.4239\/wjd.v10.i10.490","volume":"10","author":"L Athithan","year":"2019","unstructured":"Athithan L, Gulsin GS, McCann GP, Levelt E. Diabetic cardiomyopathy: Pathophysiology, theories and evidence to date. World J Diabetes. 2019;10(10):490\u2013510.","journal-title":"World J Diabetes"},{"issue":"1","key":"1188_CR38","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12933-017-0506-x","volume":"16","author":"A Lorenzo-Almor\u00f3s","year":"2017","unstructured":"Lorenzo-Almor\u00f3s A, Tu\u00f1\u00f3n J, Orejas M, Cort\u00e9s M, Egido J, Lorenzo \u00d3. Diagnostic approaches for diabetic cardiomyopathy. Cardiovasc Diabetol. 2017;16(1):28.","journal-title":"Cardiovasc Diabetol"},{"issue":"9786","key":"1188_CR39","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/S0140-6736(11)60471-6","volume":"378","author":"M Lind","year":"2011","unstructured":"Lind M, Bounias I, Olsson M, Gudbj\u00f6rnsdottir S, Svensson AM, Rosengren A. Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: an observational study. Lancet. 2011;378(9786):140\u20136.","journal-title":"Lancet"},{"issue":"7258","key":"1188_CR40","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","volume":"321","author":"IM Stratton","year":"2000","unstructured":"Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Bmj. 2000;321(7258):405\u201312.","journal-title":"Bmj"},{"issue":"1","key":"1188_CR41","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12933-017-0602-y","volume":"16","author":"JC Fruchart","year":"2017","unstructured":"Fruchart JC. Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia. Cardiovasc Diabetol. 2017;16(1):124.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"1188_CR42","doi-asserted-by":"publisher","first-page":"e12763","DOI":"10.1111\/acel.12763","volume":"17","author":"L Wu","year":"2018","unstructured":"Wu L, Wang K, Wang W, Wen Z, Wang P, Liu L, Wang DW. Glucagon-like peptide-1 ameliorates cardiac lipotoxicity in diabetic cardiomyopathy via the PPAR\u03b1 pathway. Aging Cell. 2018;17(4):e12763.","journal-title":"Aging Cell"},{"issue":"3","key":"1188_CR43","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1073\/pnas.0336724100","volume":"100","author":"BN Finck","year":"2003","unstructured":"Finck BN, Han X, Courtois M, Aimond F, Nerbonne JM, Kovacs A, Gross RW, Kelly DP. A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci U S A. 2003;100(3):1226\u201331.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"1188_CR44","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1161\/01.CIR.0000026392.80723.DC","volume":"106","author":"P Razeghi","year":"2002","unstructured":"Razeghi P, Young ME, Cockrill TC, Frazier OH, Taegtmeyer H. Downregulation of myocardial myocyte enhancer factor 2C and myocyte enhancer factor 2C-regulated gene expression in diabetic patients with nonischemic heart failure. Circulation. 2002;106(4):407\u201311.","journal-title":"Circulation"},{"issue":"4","key":"1188_CR45","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.tcm.2012.07.003","volume":"22","author":"C Riehle","year":"2012","unstructured":"Riehle C, Abel ED. PGC-1 proteins and heart failure. Trends Cardiovasc Med. 2012;22(4):98\u2013105.","journal-title":"Trends Cardiovasc Med"},{"issue":"1","key":"1188_CR46","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12933-018-0754-4","volume":"17","author":"M Waldman","year":"2018","unstructured":"Waldman M, Cohen K, Yadin D, Nudelman V, Gorfil D, Laniado-Schwartzman M, Kornwoski R, Aravot D, Abraham NG, Arad M, et al. Regulation of diabetic cardiomyopathy by caloric restriction is mediated by intracellular signaling pathways involving \u2018SIRT1 and PGC-1\u03b1\u2019. Cardiovasc Diabetol. 2018;17(1):111.","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"1188_CR47","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1161\/CIRCULATIONAHA.106.662296","volume":"115","author":"JG Duncan","year":"2007","unstructured":"Duncan JG, Fong JL, Medeiros DM, Finck BN, Kelly DP. Insulin-resistant heart exhibits a mitochondrial biogenic response driven by the peroxisome proliferator-activated receptor-alpha\/PGC-1alpha gene regulatory pathway. Circulation. 2007;115(7):909\u201317.","journal-title":"Circulation"},{"issue":"7","key":"1188_CR48","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1161\/CIRCRESAHA.110.223818","volume":"107","author":"GC Rowe","year":"2010","unstructured":"Rowe GC, Jiang A, Arany Z. PGC-1 coactivators in cardiac development and disease. Circ Res. 2010;107(7):825\u201338.","journal-title":"Circ Res"},{"issue":"1","key":"1188_CR49","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12933-019-0811-7","volume":"18","author":"Z Yin","year":"2019","unstructured":"Yin Z, Zhao Y, He M, Li H, Fan J, Nie X, Yan M, Chen C, Wang DW. MiR-30c\/PGC-1\u03b2 protects against diabetic cardiomyopathy via PPAR\u03b1. Cardiovasc Diabetol. 2019;18(1):7.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1188_CR50","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1152\/physrev.00015.2009","volume":"90","author":"GD Lopaschuk","year":"2010","unstructured":"Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiol Rev. 2010;90(1):207\u201358.","journal-title":"Physiol Rev"},{"issue":"8","key":"1188_CR51","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/S0300-9084(00)01147-0","volume":"82","author":"M Panadero","year":"2000","unstructured":"Panadero M, Herrera E, Bocos C. Peroxisome proliferator-activated receptor-alpha expression in rat liver during postnatal development. Biochimie. 2000;82(8):723\u20136.","journal-title":"Biochimie"},{"issue":"3","key":"1188_CR52","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00395-005-0520-0","volume":"100","author":"M Steinmetz","year":"2005","unstructured":"Steinmetz M, Quentin T, Poppe A, Paul T, Jux C. Changes in expression levels of genes involved in fatty acid metabolism: upregulation of all three members of the PPAR family (alpha, gamma, delta) and the newly described adiponectin receptor 2, but not adiponectin receptor 1 during neonatal cardiac development of the rat. Basic Res Cardiol. 2005;100(3):263\u20139.","journal-title":"Basic Res Cardiol"},{"issue":"4","key":"1188_CR53","doi-asserted-by":"publisher","first-page":"901","DOI":"10.2337\/diabetes.51.4.901","volume":"51","author":"DM Muoio","year":"2002","unstructured":"Muoio DM, Way JM, Tanner CJ, Winegar DA, Kliewer SA, Houmard JA, Kraus WE, Dohm GL. Peroxisome proliferator-activated receptor-alpha regulates fatty acid utilization in primary human skeletal muscle cells. Diabetes. 2002;51(4):901\u20139.","journal-title":"Diabetes"},{"issue":"1","key":"1188_CR54","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1161\/CIRCRESAHA.117.306585","volume":"117","author":"VH Lam","year":"2015","unstructured":"Lam VH, Zhang L, Huqi A, Fukushima A, Tanner BA, Onay-Besikci A, Keung W, Kantor PF, Jaswal JS, Rebeyka IM, et al. Activating PPAR\u03b1 prevents post-ischemic contractile dysfunction in hypertrophied neonatal hearts. Circ Res. 2015;117(1):41\u201351.","journal-title":"Circ Res"},{"issue":"12","key":"1188_CR55","doi-asserted-by":"publisher","first-page":"5341","DOI":"10.1210\/en.2005-0938","volume":"146","author":"J Buchanan","year":"2005","unstructured":"Buchanan J, Mazumder PK, Hu P, Chakrabarti G, Roberts MW, Yun UJ, Cooksey RC, Litwin SE, Abel ED. Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology. 2005;146(12):5341\u20139.","journal-title":"Endocrinology"},{"issue":"8","key":"1188_CR56","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1161\/CIRCULATIONAHA.115.017545","volume":"133","author":"KC Bedi Jr","year":"2016","unstructured":"Bedi KC Jr, Snyder NW, Brandimarto J, Aziz M, Mesaros C, Worth AJ, Wang LL, Javaheri A, Blair IA, Margulies KB, et al. Evidence for Intramyocardial Disruption of Lipid Metabolism and Increased Myocardial Ketone Utilization in Advanced Human Heart Failure. Circulation. 2016;133(8):706\u201316.","journal-title":"Circulation"},{"issue":"9","key":"1188_CR57","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.bbabio.2007.07.001","volume":"1767","author":"N van Vlies","year":"2007","unstructured":"van Vlies N, Ferdinandusse S, Turkenburg M, Wanders RJ, Vaz FM. PPAR alpha-activation results in enhanced carnitine biosynthesis and OCTN2-mediated hepatic carnitine accumulation. Biochim Biophys Acta. 2007;1767(9):1134\u201342.","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"1188_CR58","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1073\/pnas.96.5.2356","volume":"96","author":"Y Wang","year":"1999","unstructured":"Wang Y, Ye J, Ganapathy V, Longo N. Mutations in the organic cation\/carnitine transporter OCTN2 in primary carnitine deficiency. Proc Natl Acad Sci U S A. 1999;96(5):2356\u201360.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"1188_CR59","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1016\/j.ajpath.2011.02.020","volume":"178","author":"M Grube","year":"2011","unstructured":"Grube M, Ameling S, Noutsias M, K\u00f6ck K, Triebel I, Bonitz K, Meissner K, Jedlitschky G, Herda LR, Reinthaler M, et al. Selective regulation of cardiac organic cation transporter novel type 2 (OCTN2) in dilated cardiomyopathy. Am J Pathol. 2011;178(6):2547\u201359.","journal-title":"Am J Pathol"},{"issue":"3","key":"1188_CR60","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/cvr\/cvp132","volume":"83","author":"AD Hafstad","year":"2009","unstructured":"Hafstad AD, Khalid AM, Hagve M, Lund T, Larsen TS, Severson DL, Clarke K, Berge RK, Aasum E. Cardiac peroxisome proliferator-activated receptor-alpha activation causes increased fatty acid oxidation, reducing efficiency and post-ischaemic functional loss. Cardiovasc Res. 2009;83(3):519\u201326.","journal-title":"Cardiovasc Res"},{"issue":"8","key":"1188_CR61","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.2337\/db09-0011","volume":"58","author":"JR Ussher","year":"2009","unstructured":"Ussher JR, Koves TR, Jaswal JS, Zhang L, Ilkayeva O, Dyck JR, Muoio DM, Lopaschuk GD. Insulin-stimulated cardiac glucose oxidation is increased in high-fat diet-induced obese mice lacking malonyl CoA decarboxylase. Diabetes. 2009;58(8):1766\u201375.","journal-title":"Diabetes"},{"issue":"2","key":"1188_CR62","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.bbalip.2005.03.005","volume":"1734","author":"AN Carley","year":"2005","unstructured":"Carley AN, Severson DL. Fatty acid metabolism is enhanced in type 2 diabetic hearts. Biochim Biophys Acta. 2005;1734(2):112\u201326.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"1188_CR63","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0008-6363(97)00047-3","volume":"34","author":"WC Stanley","year":"1997","unstructured":"Stanley WC, Lopaschuk GD, McCormack JG. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res. 1997;34(1):25\u201333.","journal-title":"Cardiovasc Res"},{"issue":"2","key":"1188_CR64","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1093\/cvr\/cvp017","volume":"82","author":"JJ Wright","year":"2009","unstructured":"Wright JJ, Kim J, Buchanan J, Boudina S, Sena S, Bakirtzi K, Ilkun O, Theobald HA, Cooksey RC, Kandror KV, et al. Mechanisms for increased myocardial fatty acid utilization following short-term high-fat feeding. Cardiovasc Res. 2009;82(2):351\u201360.","journal-title":"Cardiovasc Res"},{"issue":"2","key":"1188_CR65","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1586\/14779072.4.2.161","volume":"4","author":"BN Finck","year":"2006","unstructured":"Finck BN. Effects of PPARalpha on cardiac glucose metabolism: a transcriptional equivalent of the glucose-fatty acid cycle? Expert Rev Cardiovasc Ther. 2006;4(2):161\u201371.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"10","key":"1188_CR66","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/S0006-3495(72)86164-2","volume":"12","author":"A Goldbeter","year":"1972","unstructured":"Goldbeter A, Lefever R. Dissipative structures for an allosteric model. Application to glycolytic oscillations. Biophys J. 1972;12(10):1302\u201315.","journal-title":"Biophys J"},{"issue":"4\u20135","key":"1188_CR67","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1080\/13813450701783281","volume":"113","author":"OJ How","year":"2007","unstructured":"How OJ, Larsen TS, Hafstad AD, Khalid A, Myhre ES, Murray AJ, Boardman NT, Cole M, Clarke K, Severson DL, et al. Rosiglitazone treatment improves cardiac efficiency in hearts from diabetic mice. Arch Physiol Biochem. 2007;113(4\u20135):211\u201320.","journal-title":"Arch Physiol Biochem"},{"issue":"4","key":"1188_CR68","doi-asserted-by":"publisher","first-page":"H1609-20","DOI":"10.1152\/ajpheart.00949.2007","volume":"294","author":"V Sharma","year":"2008","unstructured":"Sharma V, Dhillon P, Wambolt R, Parsons H, Brownsey R, Allard MF, McNeill JH. Metoprolol improves cardiac function and modulates cardiac metabolism in the streptozotocin-diabetic rat. Am J Physiol Heart Circ Physiol. 2008;294(4):H1609-20.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"1188_CR69","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/MCO.0000000000000235","volume":"19","author":"P Giesbertz","year":"2016","unstructured":"Giesbertz P, Daniel H. Branched-chain amino acids as biomarkers in diabetes. Curr Opin Clin Nutr Metab Care. 2016;19(1):48\u201354.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"issue":"2","key":"1188_CR70","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1093\/cvr\/cvr070","volume":"90","author":"Y Huang","year":"2011","unstructured":"Huang Y, Zhou M, Sun H, Wang Y. Branched-chain amino acid metabolism in heart disease: an epiphenomenon or a real culprit? Cardiovasc Res. 2011;90(2):220\u20133.","journal-title":"Cardiovasc Res"},{"issue":"4","key":"1188_CR71","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nm.4057","volume":"22","author":"C Jang","year":"2016","unstructured":"Jang C, Oh SF, Wada S, Rowe GC, Liu L, Chan MC, Rhee J, Hoshino A, Kim B, Ibrahim A, et al. A branched-chain amino acid metabolite drives vascular fatty acid transport and causes insulin resistance. Nat Med. 2016;22(4):421\u20136.","journal-title":"Nat Med"},{"issue":"21","key":"1188_CR72","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1161\/CIRCULATIONAHA.115.020226","volume":"133","author":"H Sun","year":"2016","unstructured":"Sun H, Olson KC, Gao C, Prosdocimo DA, Zhou M, Wang Z, Jeyaraj D, Youn JY, Ren S, Liu Y, et al. Catabolic defect of branched-chain amino acids promotes heart failure. Circulation. 2016;133(21):2038\u201349.","journal-title":"Circulation"},{"issue":"2","key":"1188_CR73","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.cmet.2016.11.005","volume":"25","author":"T Li","year":"2017","unstructured":"Li T, Zhang Z, Kolwicz SC Jr, Abell L, Roe ND, Kim M, Zhou B, Cao Y, Ritterhoff J, Gu H, et al. Defective branched-chain amino acid catabolism disrupts glucose metabolism and sensitizes the heart to ischemia-reperfusion injury. Cell Metab. 2017;25(2):374\u201385.","journal-title":"Cell Metab"},{"issue":"12","key":"1188_CR74","doi-asserted-by":"publisher","first-page":"5623","DOI":"10.7150\/thno.44836","volume":"10","author":"Y Li","year":"2020","unstructured":"Li Y, Xiong Z, Yan W, Gao E, Cheng H, Wu G, Liu Y, Zhang L, Li C, Wang S, et al. Branched chain amino acids exacerbate myocardial ischemia\/reperfusion vulnerability via enhancing GCN2\/ATF6\/PPAR-\u03b1 pathway-dependent fatty acid oxidation. Theranostics. 2020;10(12):5623\u201340.","journal-title":"Theranostics"},{"issue":"1","key":"1188_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/BJ20121098","volume":"449","author":"J Gallinetti","year":"2013","unstructured":"Gallinetti J, Harputlugil E, Mitchell JR. Amino acid sensing in dietary-restriction-mediated longevity: roles of signal-transducing kinases GCN2 and TOR. Biochem J. 2013;449(1):1\u201310.","journal-title":"Biochem J"},{"issue":"7","key":"1188_CR76","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.2337\/db15-1637","volume":"65","author":"X Chen","year":"2016","unstructured":"Chen X, Zhang F, Gong Q, Cui A, Zhuo S, Hu Z, Han Y, Gao J, Sun Y, Liu Z, et al. Hepatic ATF6 Increases Fatty Acid Oxidation to Attenuate Hepatic Steatosis in Mice Through Peroxisome Proliferator-Activated Receptor \u03b1. Diabetes. 2016;65(7):1904\u201315.","journal-title":"Diabetes"},{"issue":"4","key":"1188_CR77","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/0002-9343(54)90365-4","volume":"16","author":"RJ Bing","year":"1954","unstructured":"Bing RJ, Siegel A, Ungar I, Gilbert M. Metabolism of the human heart. II. Studies on fat, ketone and amino acid metabolism. Am J Med. 1954;16(4):504\u201315.","journal-title":"Am J Med"},{"issue":"7","key":"1188_CR78","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.2337\/dc16-0542","volume":"39","author":"S Mudaliar","year":"2016","unstructured":"Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME Study? a unifying hypothesis. Diabetes Care. 2016;39(7):1115\u201322.","journal-title":"Diabetes Care"},{"key":"1188_CR79","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/BF01483852","volume":"43","author":"W Rudolph","year":"1965","unstructured":"Rudolph W, Maas D, Richter J, Hasinger F, Hofmann H, Dohrn P. On the significance of acetoacetate and beta-hydroxybutyrate in human myocardial metabolism. Klin Wochenschr. 1965;43:445\u201351.","journal-title":"Klin Wochenschr"},{"issue":"2","key":"1188_CR80","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.cmet.2016.12.022","volume":"25","author":"P Puchalska","year":"2017","unstructured":"Puchalska P, Crawford PA. Multi-dimensional roles of ketone bodies in fuel metabolism, signaling, and therapeutics. Cell Metab. 2017;25(2):262\u201384.","journal-title":"Cell Metab"},{"issue":"11","key":"1188_CR81","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1093\/cvr\/cvz045","volume":"115","author":"KL Ho","year":"2019","unstructured":"Ho KL, Zhang L, Wagg C, Al Batran R, Gopal K, Levasseur J, Leone T, Dyck JRB, Ussher JR, Muoio DM, et al. Increased ketone body oxidation provides additional energy for the failing heart without improving cardiac efficiency. Cardiovasc Res. 2019;115(11):1606\u201316.","journal-title":"Cardiovasc Res"},{"issue":"8","key":"1188_CR82","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1161\/CIRCULATIONAHA.115.017355","volume":"133","author":"G Aubert","year":"2016","unstructured":"Aubert G, Martin OJ, Horton JL, Lai L, Vega RB, Leone TC, Koves T, Gardell SJ, Kr\u00fcger M, Hoppel CL, et al. The failing heart relies on ketone bodies as a fuel. Circulation. 2016;133(8):698\u2013705.","journal-title":"Circulation"},{"issue":"12","key":"1188_CR83","doi-asserted-by":"publisher","first-page":"4021","DOI":"10.1096\/fj.201600773R","volume":"30","author":"AJ Murray","year":"2016","unstructured":"Murray AJ, Knight NS, Cole MA, Cochlin LE, Carter E, Tchabanenko K, Pichulik T, Gulston MK, Atherton HJ, Schroeder MA, et al. Novel ketone diet enhances physical and cognitive performance. Faseb j. 2016;30(12):4021\u201332.","journal-title":"Faseb j"},{"issue":"2","key":"1188_CR84","doi-asserted-by":"publisher","first-page":"e88102","DOI":"10.1371\/journal.pone.0088102","volume":"9","author":"Z Du","year":"2014","unstructured":"Du Z, Shen A, Huang Y, Su L, Lai W, Wang P, Xie Z, Xie Z, Zeng Q, Ren H, et al. 1H-NMR-based metabolic analysis of human serum reveals novel markers of myocardial energy expenditure in heart failure patients. PLoS One. 2014;9(2):e88102.","journal-title":"PLoS One"},{"issue":"3908","key":"1188_CR85","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1126\/science.166.3908.1017","volume":"166","author":"NC Nielsen","year":"1969","unstructured":"Nielsen NC, Fleischer S. Beta-hydroxybutyrate dehydrogenase: lack in ruminant liver mitochondria. Science. 1969;166(3908):1017\u20139.","journal-title":"Science"},{"key":"1188_CR86","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1016\/S0021-9258(18)64641-1","volume":"235","author":"AL Lehninger","year":"1960","unstructured":"Lehninger AL, Sudduth HC, Wise JB. D-beta-Hydroxybutyric dehydrogenase of muitochondria. J Biol Chem. 1960;235:2450\u20135.","journal-title":"J Biol Chem"},{"issue":"11","key":"1188_CR87","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S0022-2275(20)34462-X","volume":"25","author":"SE Hall","year":"1984","unstructured":"Hall SE, Wastney ME, Bolton TM, Braaten JT, Berman M. Ketone body kinetics in humans: the effects of insulin-dependent diabetes, obesity, and starvation. J Lipid Res. 1984;25(11):1184\u201394.","journal-title":"J Lipid Res"},{"issue":"5","key":"1188_CR88","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.2337\/dc06-9909","volume":"29","author":"J Wolfsdorf","year":"2006","unstructured":"Wolfsdorf J, Glaser N, Sperling MA. Diabetic ketoacidosis in infants, children, and adolescents: a consensus statement from the American Diabetes Association. Diabetes Care. 2006;29(5):1150\u20139.","journal-title":"Diabetes Care"},{"issue":"3","key":"1188_CR89","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0735-1097(96)00214-8","volume":"28","author":"J Lommi","year":"1996","unstructured":"Lommi J, Kupari M, Koskinen P, N\u00e4veri H, Leinonen H, Pulkki K, H\u00e4rk\u00f6nen M. Blood ketone bodies in congestive heart failure. J Am Coll Cardiol. 1996;28(3):665\u201372.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"1188_CR90","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.molmet.2014.07.010","volume":"3","author":"RC Schugar","year":"2014","unstructured":"Schugar RC, Moll AR, Andr\u00e9 d\u2019Avignon D, Weinheimer CJ, Kovacs A, Crawford PA. Cardiomyocyte-specific deficiency of ketone body metabolism promotes accelerated pathological remodeling. Mol Metab. 2014;3(7):754\u201369.","journal-title":"Mol Metab"},{"issue":"11","key":"1188_CR91","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1172\/JCI6223","volume":"103","author":"S Kersten","year":"1999","unstructured":"Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest. 1999;103(11):1489\u201398.","journal-title":"J Clin Invest"},{"issue":"3","key":"1188_CR92","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1210\/en.2005-1132","volume":"147","author":"D Patsouris","year":"2006","unstructured":"Patsouris D, Reddy JK, M\u00fcller M, Kersten S. Peroxisome proliferator-activated receptor alpha mediates the effects of high-fat diet on hepatic gene expression. Endocrinology. 2006;147(3):1508\u201316.","journal-title":"Endocrinology"},{"issue":"8","key":"1188_CR93","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1210\/me.2014-1383","volume":"29","author":"M Pawlak","year":"2015","unstructured":"Pawlak M, Baug\u00e9 E, Lalloyer F, Lefebvre P, Staels B. Ketone body therapy protects from lipotoxicity and acute liver failure upon ppar\u03b1 deficiency. Mol Endocrinol. 2015;29(8):1134\u201343.","journal-title":"Mol Endocrinol"},{"issue":"9","key":"1188_CR94","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.2337\/diabetes.54.9.2514","volume":"54","author":"SY Park","year":"2005","unstructured":"Park SY, Cho YR, Finck BN, Kim HJ, Higashimori T, Hong EG, Lee MK, Danton C, Deshmukh S, Cline GW, et al. Cardiac-specific overexpression of peroxisome proliferator-activated receptor-alpha causes insulin resistance in heart and liver. Diabetes. 2005;54(9):2514\u201324.","journal-title":"Diabetes"},{"issue":"1","key":"1188_CR95","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1093\/cvr\/cvq266","volume":"89","author":"L Zhang","year":"2011","unstructured":"Zhang L, Ussher JR, Oka T, Cadete VJ, Wagg C, Lopaschuk GD. Cardiac diacylglycerol accumulation in high fat-fed mice is associated with impaired insulin-stimulated glucose oxidation. Cardiovasc Res. 2011;89(1):148\u201356.","journal-title":"Cardiovasc Res"},{"issue":"10","key":"1188_CR96","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1194\/jlr.M800147-JLR200","volume":"49","author":"TS Park","year":"2008","unstructured":"Park TS, Hu Y, Noh HL, Drosatos K, Okajima K, Buchanan J, Tuinei J, Homma S, Jiang XC, Abel ED, et al. Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J Lipid Res. 2008;49(10):2101\u201312.","journal-title":"J Lipid Res"},{"issue":"10","key":"1188_CR97","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1161\/CIRCULATIONAHA.106.645614","volume":"116","author":"JM McGavock","year":"2007","unstructured":"McGavock JM, Lingvay I, Zib I, Tillery T, Salas N, Unger R, Levine BD, Raskin P, Victor RG, Szczepaniak LS. Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation. 2007;116(10):1170\u20135.","journal-title":"Circulation"},{"key":"1188_CR98","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1172\/jci.insight.96203","volume":"2","author":"R Ji","year":"2017","unstructured":"Ji R, Akashi H, Drosatos K, Liao X, Jiang H, Kennel PJ, Brunjes DL, Castillero E, Zhang X, Deng LY, et al. Increased de novo ceramide synthesis and accumulation in failing myocardium. JCI Insight. 2017;2:9.","journal-title":"JCI Insight."},{"issue":"23","key":"1188_CR99","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1161\/CIRCULATIONAHA.111.060889","volume":"125","author":"A Chokshi","year":"2012","unstructured":"Chokshi A, Drosatos K, Cheema FH, Ji R, Khawaja T, Yu S, Kato T, Khan R, Takayama H, Kn\u00f6ll R, et al. Ventricular assist device implantation corrects myocardial lipotoxicity, reverses insulin resistance, and normalizes cardiac metabolism in patients with advanced heart failure. Circulation. 2012;125(23):2844\u201353.","journal-title":"Circulation"},{"key":"1188_CR100","doi-asserted-by":"publisher","first-page":"652097","DOI":"10.1155\/2011\/652097","volume":"2011","author":"O Lorenzo","year":"2011","unstructured":"Lorenzo O, Picatoste B, Ares-Carrasco S, Ram\u00edrez E, Egido J, Tu\u00f1\u00f3n J. Potential role of nuclear factor \u03baB in diabetic cardiomyopathy. Mediators Inflamm. 2011;2011:652097.","journal-title":"Mediators Inflamm"},{"issue":"3","key":"1188_CR101","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1385\/CT:3:3:229","volume":"3","author":"WK Jones","year":"2003","unstructured":"Jones WK, Brown M, Ren X, He S, McGuinness M. NF-kappaB as an integrator of diverse signaling pathways: the heart of myocardial signaling? Cardiovasc Toxicol. 2003;3(3):229\u201354.","journal-title":"Cardiovasc Toxicol"},{"key":"1188_CR102","doi-asserted-by":"publisher","first-page":"847827","DOI":"10.1155\/2014\/847827","volume":"2014","author":"J Fuentes-Antr\u00e1s","year":"2014","unstructured":"Fuentes-Antr\u00e1s J, Ioan AM, Tu\u00f1\u00f3n J, Egido J, Lorenzo O. Activation of toll-like receptors and inflammasome complexes in the diabetic cardiomyopathy-associated inflammation. Int J Endocrinol. 2014;2014:847827.","journal-title":"Int J Endocrinol"},{"issue":"2","key":"1188_CR103","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.freeradbiomed.2008.10.024","volume":"46","author":"C Mazi\u00e8re","year":"2009","unstructured":"Mazi\u00e8re C, Mazi\u00e8re JC. Activation of transcription factors and gene expression by oxidized low-density lipoprotein. Free Radic Biol Med. 2009;46(2):127\u201337.","journal-title":"Free Radic Biol Med"},{"issue":"14","key":"1188_CR104","doi-asserted-by":"publisher","first-page":"7850","DOI":"10.1111\/jcmm.15418","volume":"24","author":"D Yan","year":"2020","unstructured":"Yan D, Cai Y, Luo J, Liu J, Li X, Ying F, Xie X, Xu A, Ma X, Xia Z. FOXO1 contributes to diabetic cardiomyopathy via inducing imbalanced oxidative metabolism in type 1 diabetes. J Cell Mol Med. 2020;24(14):7850\u201361.","journal-title":"J Cell Mol Med"},{"issue":"2","key":"1188_CR105","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1111\/jcmm.14870","volume":"24","author":"J Luo","year":"2020","unstructured":"Luo J, Yan D, Li S, Liu S, Zeng F, Cheung CW, Liu H, Irwin MG, Huang H, Xia Z. Allopurinol reduces oxidative stress and activates Nrf2\/p62 to attenuate diabetic cardiomyopathy in rats. J Cell Mol Med. 2020;24(2):1760\u201373.","journal-title":"J Cell Mol Med"},{"issue":"1","key":"1188_CR106","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.pharmthera.2013.11.005","volume":"142","author":"S Dassanayaka","year":"2014","unstructured":"Dassanayaka S, Jones SP. O-GlcNAc and the cardiovascular system. Pharmacol Ther. 2014;142(1):62\u201371.","journal-title":"Pharmacol Ther"},{"issue":"4","key":"1188_CR107","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1161\/CIRCULATIONAHA.105.537894","volume":"113","author":"J Wang","year":"2006","unstructured":"Wang J, Song Y, Elsherif L, Song Z, Zhou G, Prabhu SD, Saari JT, Cai L. Cardiac metallothionein induction plays the major role in the prevention of diabetic cardiomyopathy by zinc supplementation. Circulation. 2006;113(4):544\u201354.","journal-title":"Circulation"},{"issue":"3","key":"1188_CR108","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1093\/cvr\/cvp305","volume":"85","author":"N Mariappan","year":"2010","unstructured":"Mariappan N, Elks CM, Sriramula S, Guggilam A, Liu Z, Borkhsenious O, Francis J. NF-kappaB-induced oxidative stress contributes to mitochondrial and cardiac dysfunction in type II diabetes. Cardiovasc Res. 2010;85(3):473\u201383.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"1188_CR109","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/nyas.13386","volume":"1403","author":"W Liu","year":"2017","unstructured":"Liu W, Chen P, Deng J, Lv J, Liu J. Resveratrol and polydatin as modulators of Ca(2+) mobilization in the cardiovascular system. Ann N Y Acad Sci. 2017;1403(1):82\u201391.","journal-title":"Ann N Y Acad Sci"},{"key":"1188_CR110","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.yjmcc.2017.02.004","volume":"105","author":"G Kanaporis","year":"2017","unstructured":"Kanaporis G, Blatter LA. Membrane potential determines calcium alternans through modulation of SR Ca(2+) load and L-type Ca(2+) current. J Mol Cell Cardiol. 2017;105:49\u201358.","journal-title":"J Mol Cell Cardiol"},{"issue":"5","key":"1188_CR111","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.2337\/diabetes.53.5.1336","volume":"53","author":"G Ye","year":"2004","unstructured":"Ye G, Metreveli NS, Donthi RV, Xia S, Xu M, Carlson EC, Epstein PN. Catalase protects cardiomyocyte function in models of type 1 and type 2 diabetes. Diabetes. 2004;53(5):1336\u201343.","journal-title":"Diabetes"},{"issue":"3","key":"1188_CR112","doi-asserted-by":"publisher","first-page":"777","DOI":"10.2337\/diabetes.52.3.777","volume":"52","author":"G Ye","year":"2003","unstructured":"Ye G, Metreveli NS, Ren J, Epstein PN. Metallothionein prevents diabetes-induced deficits in cardiomyocytes by inhibiting reactive oxygen species production. Diabetes. 2003;52(3):777\u201383.","journal-title":"Diabetes"},{"issue":"2","key":"1188_CR113","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1093\/cvr\/cvm001","volume":"77","author":"A Van den Bergh","year":"2008","unstructured":"Van den Bergh A, Vanderper A, Vangheluwe P, Desjardins F, Nevelsteen I, Verreth W, Wuytack F, Holvoet P, Flameng W, Balligand JL, et al. Dyslipidaemia in type II diabetic mice does not aggravate contractile impairment but increases ventricular stiffness. Cardiovasc Res. 2008;77(2):371\u20139.","journal-title":"Cardiovasc Res"},{"issue":"12","key":"1188_CR114","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.2337\/diabetes.53.12.3201","volume":"53","author":"DD Belke","year":"2004","unstructured":"Belke DD, Swanson EA, Dillmann WH. Decreased sarcoplasmic reticulum activity and contractility in diabetic db\/db mouse heart. Diabetes. 2004;53(12):3201\u20138.","journal-title":"Diabetes"},{"issue":"6","key":"1188_CR115","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1161\/01.RES.0000062469.83985.9B","volume":"92","author":"V Piacentino","year":"2003","unstructured":"Piacentino V, Weber CR, Chen X, Weisser-Thomas J, Margulies KB, Bers DM, Houser SR. Cellular basis of abnormal calcium transients of failing human ventricular myocytes. Circ Res. 2003;92(6):651\u20138.","journal-title":"Circ Res"},{"issue":"27","key":"1188_CR116","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonz\u00e1lez-Juanatey JR, Harjola VP, Jankowska EA, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129\u2013200.","journal-title":"Eur Heart J"},{"issue":"10","key":"1188_CR117","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1161\/CIRCULATIONAHA.114.014796","volume":"132","author":"MA Cavender","year":"2015","unstructured":"Cavender MA, Steg PG, Smith SC Jr, Eagle K, Ohman EM, Goto S, Kuder J, Im K, Wilson PW, Bhatt DL. Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the reduction of atherothrombosis for continued health (REACH) Registry. Circulation. 2015;132(10):923\u201331.","journal-title":"Circulation"},{"issue":"8","key":"1188_CR118","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1016\/S0735-1097(02)02304-5","volume":"40","author":"AP Maggioni","year":"2002","unstructured":"Maggioni AP, Anand I, Gottlieb SO, Latini R, Tognoni G, Cohn JN. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol. 2002;40(8):1414\u201321.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"1188_CR119","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/S0002-8703(03)00403-4","volume":"146","author":"SJ Haas","year":"2003","unstructured":"Haas SJ, Vos T, Gilbert RE, Krum H. Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J. 2003;146(5):848\u201353.","journal-title":"Am Heart J"},{"issue":"1","key":"1188_CR120","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1005136","volume":"365","author":"NA Martinson","year":"2011","unstructured":"Martinson NA, Barnes GL, Moulton LH, Msandiwa R, Hausler H, Ram M, McIntyre JA, Gray GE, Chaisson RE. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med. 2011;365(1):11\u201320.","journal-title":"N Engl J Med"},{"issue":"1","key":"1188_CR121","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/ejhf.657","volume":"19","author":"A Jorsal","year":"2017","unstructured":"Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, H\u00e4nselmann A, Nilsson B, M\u00f8ller JE, Hjort J, Rasmussen J, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail. 2017;19(1):69\u201377.","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"1188_CR122","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1001\/jama.2016.10260","volume":"316","author":"KB Margulies","year":"2016","unstructured":"Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, Mann DL, Whellan DJ, Kiernan MS, Felker GM, et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. Jama. 2016;316(5):500\u20138.","journal-title":"Jama"},{"issue":"18","key":"1188_CR123","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.114.010389","volume":"130","author":"BM Scirica","year":"2014","unstructured":"Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, Udell JA, Mosenzon O, Im K, Umez-Eronini AA, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130(18):1579\u201388.","journal-title":"Circulation"},{"issue":"14","key":"1188_CR124","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317\u201326.","journal-title":"N Engl J Med"},{"issue":"24","key":"1188_CR125","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1056\/NEJMoa072761","volume":"356","author":"SE Nissen","year":"2007","unstructured":"Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457\u201371.","journal-title":"N Engl J Med"},{"issue":"14","key":"1188_CR126","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1001\/archinternmed.2010.207","volume":"170","author":"SE Nissen","year":"2010","unstructured":"Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med. 2010;170(14):1191\u2013201.","journal-title":"Arch Intern Med"},{"issue":"4","key":"1188_CR127","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jama.2010.920","volume":"304","author":"DJ Graham","year":"2010","unstructured":"Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, Kelman JA. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. Jama. 2010;304(4):411\u20138.","journal-title":"Jama"},{"issue":"8","key":"1188_CR128","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1161\/CIRCULATIONAHA.112.000678","volume":"128","author":"RG Bach","year":"2013","unstructured":"Bach RG, Brooks MM, Lombardero M, Genuth S, Donner TW, Garber A, Kennedy L, Monrad ES, Pop-Busui R, Kelsey SF, et al. Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation. 2013;128(8):785\u201394.","journal-title":"Circulation"},{"issue":"7","key":"1188_CR129","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1093\/eurheartj\/ehp604","volume":"31","author":"M Komajda","year":"2010","unstructured":"Komajda M, McMurray JJ, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ, Curtis PS, Jones NP, Home PD. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J. 2010;31(7):824\u201331.","journal-title":"Eur Heart J"},{"issue":"9593","key":"1188_CR130","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/S0140-6736(07)61514-1","volume":"370","author":"RM Lago","year":"2007","unstructured":"Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 2007;370(9593):1129\u201336.","journal-title":"Lancet"},{"issue":"5","key":"1188_CR131","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/ejhf.1170","volume":"20","author":"PM Seferovi\u0107","year":"2018","unstructured":"Seferovi\u0107 PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J, Paulus WJ, Komajda M, Cosentino F, de Boer RA, et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20(5):853\u201372.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"1188_CR132","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1161\/01.ATV.0000103951.67680.B1","volume":"24","author":"M Ricote","year":"2004","unstructured":"Ricote M, Valledor AF, Glass CK. Decoding transcriptional programs regulated by PPARs and LXRs in the macrophage: effects on lipid homeostasis, inflammation, and atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24(2):230\u20139.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"1188_CR133","first-page":"F1036-46","volume":"281","author":"Y Guan","year":"2001","unstructured":"Guan Y, Zhang Y, Schneider A, Davis L, Breyer RM, Breyer MD. Peroxisome proliferator-activated receptor-gamma activity is associated with renal microvasculature. Am J Physiol Renal Physiol. 2001;281(6):F1036-46.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"38","key":"1188_CR134","doi-asserted-by":"publisher","first-page":"35105","DOI":"10.1074\/jbc.M201575200","volume":"277","author":"LA Cowart","year":"2002","unstructured":"Cowart LA, Wei S, Hsu MH, Johnson EF, Krishna MU, Falck JR, Capdevila JH. The CYP4A isoforms hydroxylate epoxyeicosatrienoic acids to form high affinity peroxisome proliferator-activated receptor ligands. J Biol Chem. 2002;277(38):35105\u201312.","journal-title":"J Biol Chem"},{"issue":"19","key":"1188_CR135","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","volume":"98","author":"B Staels","year":"1998","unstructured":"Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98(19):2088\u201393.","journal-title":"Circulation"},{"issue":"6","key":"1188_CR136","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1002\/med.1025","volume":"21","author":"AB Jones","year":"2001","unstructured":"Jones AB. Peroxisome proliferator-activated receptor (PPAR) modulators: diabetes and beyond. Med Res Rev. 2001;21(6):540\u201352.","journal-title":"Med Res Rev"},{"issue":"Pt 5","key":"1188_CR137","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1258\/acb.2012.011163","volume":"49","author":"V Ncube","year":"2012","unstructured":"Ncube V, Starkey B, Wang T. Effect of fenofibrate treatment for hyperlipidaemia on serum creatinine and cystatin C. Ann Clin Biochem. 2012;49(Pt 5):491\u20133.","journal-title":"Ann Clin Biochem"},{"issue":"1","key":"1188_CR138","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/07853890.2017.1325967","volume":"50","author":"M Mazidi","year":"2018","unstructured":"Mazidi M, Kengne AP, Mikhailidis DP, Cicero AF, Banach M. Effects of selected dietary constituents on high-sensitivity C-reactive protein levels in U.S. adults. Ann Med. 2018;50(1):1\u20136.","journal-title":"Ann Med"},{"issue":"8","key":"1188_CR139","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/nrendo.2010.89","volume":"6","author":"A Hiukka","year":"2010","unstructured":"Hiukka A, Maranghi M, Matikainen N, Taskinen MR. PPARalpha: an emerging therapeutic target in diabetic microvascular damage. Nat Rev Endocrinol. 2010;6(8):454\u201363.","journal-title":"Nat Rev Endocrinol"},{"issue":"9500","key":"1188_CR140","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","volume":"366","author":"A Keech","year":"2005","unstructured":"Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849\u201361.","journal-title":"Lancet"},{"issue":"9600","key":"1188_CR141","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(07)61607-9","volume":"370","author":"AC Keech","year":"2007","unstructured":"Keech AC, Mitchell P, Summanen PA, O\u2019Day J, Davis TM, Moffitt MS, Taskinen MR, Simes RJ, Tse D, Williamson E, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007;370(9600):1687\u201397.","journal-title":"Lancet"},{"issue":"20","key":"1188_CR142","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","volume":"317","author":"MH Frick","year":"1987","unstructured":"Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317(20):1237\u201345.","journal-title":"N Engl J Med"},{"issue":"6","key":"1188_CR143","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1056\/NEJM199908053410604","volume":"341","author":"HB Rubins","year":"1999","unstructured":"Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341(6):410\u20138.","journal-title":"N Engl J Med"},{"issue":"9","key":"1188_CR144","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nrendo.2009.151","volume":"5","author":"TA Jacobson","year":"2009","unstructured":"Jacobson TA. Myopathy with statin-fibrate combination therapy: clinical considerations. Nat Rev Endocrinol. 2009;5(9):507\u201318.","journal-title":"Nat Rev Endocrinol"},{"issue":"9729","key":"1188_CR145","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/S0140-6736(10)60656-3","volume":"375","author":"M Jun","year":"2010","unstructured":"Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, Grobbee DE, Cass A, Chalmers J, Perkovic V. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010;375(9729):1875\u201384.","journal-title":"Lancet"},{"issue":"7","key":"1188_CR146","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1056\/NEJMc1006407","volume":"363","author":"FM Sacks","year":"2010","unstructured":"Sacks FM, Carey VJ, Fruchart JC. Combination lipid therapy in type 2 diabetes. N Engl J Med. 2010;363(7):692\u20134 (author reply 94\u20135).","journal-title":"N Engl J Med"},{"issue":"7","key":"1188_CR147","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1056\/NEJMc1006407","volume":"363","author":"CH Saely","year":"2010","unstructured":"Saely CH, Rein P, Drexel H. Combination lipid therapy in type 2 diabetes. N Engl J Med. 2010;363(7):692 (author reply 94\u20135).","journal-title":"N Engl J Med"},{"issue":"1","key":"1188_CR148","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","volume":"102","author":"Secondary prevention by","year":"2000","unstructured":"Secondary prevention by. raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation. 2000;102(1):21\u20137.","journal-title":"Circulation"},{"issue":"20","key":"1188_CR149","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1056\/NEJM198705143162003","volume":"316","author":"G Geiger","year":"1987","unstructured":"Geiger G, Lettvin JY. Peripheral vision in persons with dyslexia. N Engl J Med. 1987;316(20):1238\u201343.","journal-title":"N Engl J Med"},{"issue":"1","key":"1188_CR150","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11883-020-0823-5","volume":"22","author":"S Yamashita","year":"2020","unstructured":"Yamashita S, Masuda D, Matsuzawa Y. Pemafibrate, a new selective PPAR\u03b1 modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases. Curr Atheroscler Rep. 2020;22(1):5.","journal-title":"Curr Atheroscler Rep"},{"issue":"1","key":"1188_CR151","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12933-019-0864-7","volume":"18","author":"JC Fruchart","year":"2019","unstructured":"Fruchart JC, Santos RD, Aguilar-Salinas C, Aikawa M, Al Rasadi K, Amarenco P, Barter PJ, Ceska R, Corsini A, Despr\u00e9s JP, et al. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM\u03b1) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation. Cardiovasc Diabetol. 2019;18(1):71.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"1188_CR152","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jphs.2017.02.003","volume":"133","author":"K Takei","year":"2017","unstructured":"Takei K, Nakagawa Y, Wang Y, Han SI, Satoh A, Sekiya M, Matsuzaka T, Shimano H. Effects of K-877, a novel selective PPAR\u03b1 modulator, on small intestine contribute to the amelioration of hyperlipidemia in low-density lipoprotein receptor knockout mice. J Pharmacol Sci. 2017;133(4):214\u201322.","journal-title":"J Pharmacol Sci"},{"issue":"5","key":"1188_CR153","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1053\/j.gastro.2014.07.044","volume":"147","author":"FM Fisher","year":"2014","unstructured":"Fisher FM, Chui PC, Nasser IA, Popov Y, Cunniff JC, Lundasen T, Kharitonenkov A, Schuppan D, Flier JS, Maratos-Flier E. Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets. Gastroenterology. 2014;147(5):1073\u201383.e6.","journal-title":"Gastroenterology"},{"issue":"20","key":"1188_CR154","doi-asserted-by":"publisher","first-page":"17982","DOI":"10.1074\/jbc.M212191200","volume":"278","author":"N Vu-Dac","year":"2003","unstructured":"Vu-Dac N, Gervois P, Jakel H, Nowak M, Bauge E, Dehondt H, Staels B, Pennacchio LA, Rubin EM, Fruchart-Najib J, et al. Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators. J Biol Chem. 2003;278(20):17982\u20135.","journal-title":"J Biol Chem"},{"key":"1188_CR155","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.atherosclerosis.2016.02.029","volume":"249","author":"S Ishibashi","year":"2016","unstructured":"Ishibashi S, Yamashita S, Arai H, Araki E, Yokote K, Suganami H, Fruchart JC, Kodama T. Effects of K-877, a novel selective PPAR\u03b1 modulator (SPPARM\u03b1), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial. Atherosclerosis. 2016;249:36\u201343.","journal-title":"Atherosclerosis"},{"issue":"6","key":"1188_CR156","doi-asserted-by":"publisher","first-page":"521","DOI":"10.5551\/jat.44412","volume":"25","author":"H Arai","year":"2018","unstructured":"Arai H, Yamashita S, Yokote K, Araki E, Suganami H, Ishibashi S. Efficacy and safety of pemafibrate versus fenofibrate in patients with high triglyceride and low HDL cholesterol levels: a multicenter, placebo-controlled, double-blind, randomized trial. J Atheroscler Thromb. 2018;25(6):521\u201338.","journal-title":"J Atheroscler Thromb"},{"issue":"1","key":"1188_CR157","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jacl.2017.10.006","volume":"12","author":"S Ishibashi","year":"2018","unstructured":"Ishibashi S, Arai H, Yokote K, Araki E, Suganami H, Yamashita S. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor \u03b1 modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. J Clin Lipidol. 2018;12(1):173\u201384.","journal-title":"J Clin Lipidol"},{"issue":"1","key":"1188_CR158","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12933-019-0845-x","volume":"18","author":"S Ida","year":"2019","unstructured":"Ida S, Kaneko R, Murata K. Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis. Cardiovasc Diabetol. 2019;18(1):38.","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"1188_CR159","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1111\/dom.13686","volume":"21","author":"E Araki","year":"2019","unstructured":"Araki E, Yamashita S, Arai H, Yokote K, Satoh J, Inoguchi T, Nakamura J, Maegawa H, Yoshioka N, Tanizawa Y, et al. Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52-week data from the PROVIDE study. Diabetes Obes Metab. 2019;21(7):1737\u201344.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"1188_CR160","doi-asserted-by":"publisher","first-page":"389","DOI":"10.5551\/jat.48918","volume":"26","author":"S Yamashita","year":"2019","unstructured":"Yamashita S, Masuda D, Matsuzawa Y. Clinical applications of a novel selective PPAR\u03b1 modulator, pemafibrate, in dyslipidemia and metabolic diseases. J Atheroscler Thromb. 2019;26(5):389\u2013402.","journal-title":"J Atheroscler Thromb"},{"key":"1188_CR161","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.atherosclerosis.2017.03.032","volume":"261","author":"H Arai","year":"2017","unstructured":"Arai H, Yamashita S, Yokote K, Araki E, Suganami H, Ishibashi S. Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia. Atherosclerosis. 2017;261:144\u201352.","journal-title":"Atherosclerosis"},{"issue":"3","key":"1188_CR162","doi-asserted-by":"publisher","first-page":"538","DOI":"10.2337\/dc17-1589","volume":"41","author":"E Araki","year":"2018","unstructured":"Araki E, Yamashita S, Arai H, Yokote K, Satoh J, Inoguchi T, Nakamura J, Maegawa H, Yoshioka N, Tanizawa Y, et al. Effects of pemafibrate, a novel selective PPAR\u03b1 modulator, on lipid and glucose metabolism in patients with type 2 diabetes and hypertriglyceridemia: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2018;41(3):538\u201346.","journal-title":"Diabetes Care"},{"issue":"5","key":"1188_CR163","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/j.jacl.2018.06.010","volume":"12","author":"S Yamashita","year":"2018","unstructured":"Yamashita S, Arai H, Yokote K, Araki E, Suganami H, Ishibashi S. Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia. J Clin Lipidol. 2018;12(5):1267\u201379.e4.","journal-title":"J Clin Lipidol"},{"issue":"3","key":"1188_CR164","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1161\/01.ATV.16.3.351","volume":"16","author":"M Benderly","year":"1996","unstructured":"Benderly M, Graff E, Reicher-Reiss H, Behar S, Brunner D, Goldbourt U. Fibrinogen is a predictor of mortality in coronary heart disease patients. The Bezafibrate Infarction Prevention (BIP) Study Group. Arterioscler Thromb Vasc Biol. 1996;16(3):351\u20136.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"1188_CR165","first-page":"257","volume":"36","author":"A Tofield","year":"2015","unstructured":"Tofield A. Recurrent atrial fibrillation reduced after renal denervation with pulmonary vein ablation in select patients. Eur Heart J. 2015;36(5):257.","journal-title":"Eur Heart J"},{"issue":"6","key":"1188_CR166","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1111\/jdi.12845","volume":"9","author":"I Matsuba","year":"2018","unstructured":"Matsuba I, Matsuba R, Ishibashi S, Yamashita S, Arai H, Yokote K, Suganami H, Araki E. Effects of a novel selective peroxisome proliferator-activated receptor-\u03b1 modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance. J Diabetes Investig. 2018;9(6):1323\u201332.","journal-title":"J Diabetes Investig"},{"key":"1188_CR167","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ahj.2018.09.011","volume":"206","author":"AD Pradhan","year":"2018","unstructured":"Pradhan AD, Paynter NP, Everett BM, Glynn RJ, Amarenco P, Elam M, Ginsberg H, Hiatt WR, Ishibashi S, Koenig W, et al. Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. Am Heart J. 2018;206:80\u201393.","journal-title":"Am Heart J"},{"issue":"6","key":"1188_CR168","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/j.1464-5491.2009.02748.x","volume":"26","author":"J Cuthbertson","year":"2009","unstructured":"Cuthbertson J, Patterson S, O\u2019Harte FP, Bell PM. Investigation of the effect of oral metformin on dipeptidylpeptidase-4 (DPP-4) activity in Type 2 diabetes. Diabet Med. 2009;26(6):649\u201354.","journal-title":"Diabet Med"},{"key":"1188_CR169","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1172\/jci.insight.93936","volume":"3","author":"E Bahne","year":"2018","unstructured":"Bahne E, Sun EWL, Young RL, Hansen M, Sonne DP, Hansen JS, Rohde U, Liou AP, Jackson ML, de Fontgalland D, et al. Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes. JCI Insight. 2018;3:23.","journal-title":"JCI Insight."},{"issue":"2","key":"1188_CR170","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s00125-010-1937-z","volume":"54","author":"A Maida","year":"2011","unstructured":"Maida A, Lamont BJ, Cao X, Drucker DJ. Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-\u03b1 in mice. Diabetologia. 2011;54(2):339\u201349.","journal-title":"Diabetologia"},{"issue":"7","key":"1188_CR171","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.2337\/db09-1679","volume":"59","author":"M Takashima","year":"2010","unstructured":"Takashima M, Ogawa W, Hayashi K, Inoue H, Kinoshita S, Okamoto Y, Sakaue H, Wataoka Y, Emi A, Senga Y, et al. Role of KLF15 in regulation of hepatic gluconeogenesis and metformin action. Diabetes. 2010;59(7):1608\u201315.","journal-title":"Diabetes"},{"issue":"3","key":"1188_CR172","doi-asserted-by":"publisher","first-page":"e91006","DOI":"10.1371\/journal.pone.0091006","volume":"9","author":"Y Hatazawa","year":"2014","unstructured":"Hatazawa Y, Tadaishi M, Nagaike Y, Morita A, Ogawa Y, Ezaki O, Takai-Igarashi T, Kitaura Y, Shimomura Y, Kamei Y, et al. PGC-1\u03b1-mediated branched-chain amino acid metabolism in the skeletal muscle. PLoS One. 2014;9(3):e91006.","journal-title":"PLoS One"},{"issue":"2","key":"1188_CR173","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S0003-9861(02)00472-1","volume":"407","author":"R Kobayashi","year":"2002","unstructured":"Kobayashi R, Murakami T, Obayashi M, Nakai N, Jaskiewicz J, Fujiwara Y, Shimomura Y, Harris RA. Clofibric acid stimulates branched-chain amino acid catabolism by three mechanisms. Arch Biochem Biophys. 2002;407(2):231\u201340.","journal-title":"Arch Biochem Biophys"},{"issue":"30","key":"1188_CR174","doi-asserted-by":"publisher","first-page":"5935","DOI":"10.1523\/JNEUROSCI.2904-18.2019","volume":"39","author":"J Zemdegs","year":"2019","unstructured":"Zemdegs J, Martin H, Pintana H, Bullich S, Manta S, Marqu\u00e9s MA, Moro C, Lay\u00e9 S, Ducrocq F, Chattipakorn N, et al. Metformin promotes anxiolytic and antidepressant-like responses in insulin-resistant mice by decreasing circulating branched-chain amino acids. J Neurosci. 2019;39(30):5935\u201348.","journal-title":"J Neurosci"},{"issue":"12","key":"1188_CR175","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/nrendo.2014.171","volume":"10","author":"CJ Lynch","year":"2014","unstructured":"Lynch CJ, Adams SH. Branched-chain amino acids in metabolic signalling and insulin resistance. Nat Rev Endocrinol. 2014;10(12):723\u201336.","journal-title":"Nat Rev Endocrinol"},{"issue":"10","key":"1188_CR176","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1093\/eurheartj\/ehn156","volume":"29","author":"MR MacDonald","year":"2008","unstructured":"MacDonald MR, Petrie MC, Hawkins NM, Petrie JR, Fisher M, McKelvie R, Aguilar D, Krum H, McMurray JJ. Diabetes, left ventricular systolic dysfunction, and chronic heart failure. Eur Heart J. 2008;29(10):1224\u201340.","journal-title":"Eur Heart J"},{"issue":"7","key":"1188_CR177","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1080\/13543776.2016.1192130","volume":"26","author":"EJ Park","year":"2016","unstructured":"Park EJ, Lim SM, Lee KC, Na DH. Exendins and exendin analogs for diabetic therapy: a patent review (2012\u20132015). Expert Opin Ther Pat. 2016;26(7):833\u201342.","journal-title":"Expert Opin Ther Pat"},{"issue":"6","key":"1188_CR178","doi-asserted-by":"publisher","first-page":"C508-18","DOI":"10.1152\/ajpcell.00248.2012","volume":"304","author":"CW Younce","year":"2013","unstructured":"Younce CW, Burmeister MA, Ayala JE. Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and activation of SERCA2a. Am J Physiol Cell Physiol. 2013;304(6):C508-18.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"9","key":"1188_CR179","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.cardfail.2010.05.027","volume":"16","author":"MA Mamas","year":"2010","unstructured":"Mamas MA, Deaton C, Rutter MK, Yuille M, Williams SG, Ray SG, New J, Gibson JM, Neyses L. Impaired glucose tolerance and insulin resistance in heart failure: underrecognized and undertreated? J Card Fail. 2010;16(9):761\u20138.","journal-title":"J Card Fail"},{"issue":"13","key":"1188_CR180","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jacc.2014.04.083","volume":"64","author":"W Doehner","year":"2014","unstructured":"Doehner W, Frenneaux M, Anker SD. Metabolic impairment in heart failure: the myocardial and systemic perspective. J Am Coll Cardiol. 2014;64(13):1388\u2013400.","journal-title":"J Am Coll Cardiol"},{"key":"1188_CR181","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.2147\/DDDT.S166765","volume":"13","author":"C Antza","year":"2019","unstructured":"Antza C, Nirantharakumar K, Doundoulakis I, Tahrani AA, Toulis KA. The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date. Drug Des Devel Ther. 2019;13:2985\u201396.","journal-title":"Drug Des Devel Ther"},{"issue":"18","key":"1188_CR182","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1161\/CIRCULATIONAHA.107.739938","volume":"117","author":"K Ban","year":"2008","unstructured":"Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 2008;117(18):2340\u201350.","journal-title":"Circulation"},{"issue":"4","key":"1188_CR183","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"23","key":"1188_CR184","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, K\u00f8ber LV, Lawson FC, Ping L, Wei X, Lewis EF, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247\u201357.","journal-title":"N Engl J Med"},{"issue":"13","key":"1188_CR185","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228\u201339.","journal-title":"N Engl J Med"},{"issue":"19","key":"1188_CR186","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344.","journal-title":"N Engl J Med"},{"issue":"10166","key":"1188_CR187","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31\u20139.","journal-title":"Lancet"},{"issue":"22","key":"1188_CR188","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"7","key":"1188_CR189","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"4","key":"1188_CR190","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.117.032038","volume":"137","author":"KW Mahaffey","year":"2018","unstructured":"Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Fabbrini E, Sun T, Li Q, et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation. 2018;137(4):323\u201334.","journal-title":"Circulation"},{"issue":"3","key":"1188_CR191","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","volume":"61","author":"L Uthman","year":"2018","unstructured":"Uthman L, Baartscheer A, Bleijlevens B, Schumacher CA, Fiolet JWT, Koeman A, Jancev M, Hollmann MW, Weber NC, Coronel R, et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na(+)\/H(+) exchanger, lowering of cytosolic Na(+) and vasodilation. Diabetologia. 2018;61(3):722\u201326.","journal-title":"Diabetologia"},{"issue":"16","key":"1188_CR192","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1161\/CIRCULATIONAHA.117.030418","volume":"136","author":"M Packer","year":"2017","unstructured":"Packer M. Activation and inhibition of sodium-hydrogen exchanger is a mechanism that links the pathophysiology and treatment of diabetes mellitus with that of heart failure. Circulation. 2017;136(16):1548\u201359.","journal-title":"Circulation"},{"issue":"17","key":"1188_CR193","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","volume":"139","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 2019;139(17):2022\u201331.","journal-title":"Circulation"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-020-01188-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12933-020-01188-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-020-01188-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,18]],"date-time":"2021-04-18T18:37:08Z","timestamp":1618771028000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-020-01188-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,4]]},"references-count":193,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1188"],"URL":"https:\/\/doi.org\/10.1186\/s12933-020-01188-0","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,4]]},"assertion":[{"value":"14 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have approved the final manuscript for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}